Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. [electronic resource]
Producer: 20130510Description: 3-14 p. digitalISSN:- 1941-837X
- Aged
- Aged, 80 and over
- Alendronate -- economics
- Antibodies, Monoclonal, Humanized -- economics
- Bone Density Conservation Agents -- economics
- Cohort Studies
- Cost-Benefit Analysis
- Denosumab
- Etidronic Acid -- analogs & derivatives
- Female
- Humans
- Markov Chains
- Middle Aged
- Models, Econometric
- Ontario
- Osteoporosis, Postmenopausal -- drug therapy
- Quality-Adjusted Life Years
- Risedronic Acid
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.